Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

细胞周期蛋白依赖激酶6 帕博西利布 替莫唑胺 医学 药理学 胶质瘤 癌症研究 流出 癌症 细胞周期 内科学 细胞周期蛋白依赖激酶 乳腺癌 生物 转移性乳腺癌 遗传学
作者
Thomas J. Raub,Graham N. Wishart,Palaniappan Kulanthaivel,Brian A. Staton,Rose T. Ajamie,Geri A. Sawada,Lawrence M. Gelbert,Harlan E. Shannon,Concepcion Sanchez-Martinez,Alfonso de Dios
出处
期刊:Drug Metabolism and Disposition [American Society for Pharmacology and Experimental Therapeutics]
卷期号:43 (9): 1360-1371 被引量:298
标识
DOI:10.1124/dmd.114.062745
摘要

Effective treatments for primary brain tumors and brain metastases represent a major unmet medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway using a potent CDK4 and CDK6 kinase inhibitor has potential for treating primary central nervous system tumors such as glioblastoma and some peripheral tumors with high incidence of brain metastases. We compared central nervous system exposures of two orally bioavailable CDK4 and CDK6 inhibitors: abemaciclib, which is currently in advanced clinical development, and palbociclib (IBRANCE; Pfizer), which was recently approved by the U.S. Food and Drug Administration. Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ). Both inhibitors were substrates for xenobiotic efflux transporters P-glycoprotein and breast cancer resistant protein expressed at the blood–brain barrier. Brain Kp,uu values were less than 0.2 after an equimolar intravenous dose indicative of active efflux but were approximately 10-fold greater for abemaciclib than palbociclib. Kp,uu increased 2.8- and 21-fold, respectively, when similarly dosed in P-gp–deficient mice. Abemaciclib had brain area under the curve (0–24 hours) Kp,uu values of 0.03 in mice and 0.11 in rats after a 30 mg/kg p.o. dose. Orally dosed abemaciclib significantly increased survival in a rat orthotopic U87MG xenograft model compared with vehicle-treated animals, and efficacy coincided with a dose-dependent increase in unbound plasma and brain exposures in excess of the CDK4 and CDK6 Ki values. Abemaciclib increased survival time of intracranial U87MG tumor-bearing rats similar to TMZ, and the combination of abemaciclib and TMZ was additive or greater than additive. These data show that abemaciclib crosses the blood–brain barrier and confirm that both CDK4 and CDK6 inhibitors reach unbound brain levels in rodents that are expected to produce enzyme inhibition; however, abemaciclib brain levels are reached more efficiently at presumably lower doses than palbociclib and are potentially on target for a longer period of time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欣喜的半山的应助被zcywaup采纳,获得30
1秒前
科研通AI65的应助被木子采纳,获得10
1秒前
2秒前
Jennie369完成签到,获得积分10
2秒前
CipherSage的应助被忧郁丹翠采纳,获得10
2秒前
飞云之下完成签到,获得积分10
3秒前
3秒前
3秒前
xx完成签到,获得积分10
4秒前
姐夫开花店完成签到 ,获得积分10
4秒前
辣酒猫发布了新的文献求助10
5秒前
sandman完成签到,获得积分10
5秒前
科研通AI6.2的应助被wxtlzzdp采纳,获得10
5秒前
旧时光完成签到,获得积分10
6秒前
zkylh完成签到,获得积分10
6秒前
ban完成签到,获得积分20
6秒前
wang发布了新的文献求助10
6秒前
大聪明发布了新的文献求助10
7秒前
congcong发布了新的文献求助10
8秒前
波吉完成签到,获得积分10
9秒前
syf关闭了syf的文献求助
9秒前
霸气胡萝卜完成签到,获得积分10
9秒前
坚强皮卡丘完成签到,获得积分10
10秒前
细心的道天的应助被meng采纳,获得10
10秒前
hy完成签到 ,获得积分10
10秒前
11秒前
liuyuhongxiao完成签到,获得积分10
11秒前
汉堡包的应助被帅气的白风采纳,获得10
13秒前
无情丹秋发布了新的文献求助10
13秒前
辣酒猫完成签到,获得积分10
13秒前
FashionBoy的应助被sui采纳,获得30
13秒前
13秒前
烂漫世界完成签到,获得积分20
14秒前
Ava的应助被六十一采纳,获得10
14秒前
14秒前
筷碗完成签到 ,获得积分10
14秒前
14秒前
JX完成签到,获得积分10
14秒前
paperman完成签到,获得积分20
14秒前
ban关注了科研通微信公众号
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178139
求助须知:如何正确求助?哪些是违规求助? 9568884
关于积分的说明 21801751
捐赠科研通 7773042
什么是DOI,文献DOI怎么找? 3432685
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478223